Characterization of monocyte-derived dendritic cel... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals

Full text
Author(s):
da Silva, Lais Teodoro [1] ; da Silva, Wanessa Cardoso [1] ; de Almeida, Alexandre [1] ; Reis, Denise da Silva [1] ; Santllo, Bruna Tereso [1] ; Rigato, Paula Ordonhez [2] ; da Silva Duarte, Alberto Jose [1] ; Oshiro, Telma Miyuki [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Lab Invest Dermatol & Imunodeficiencias, BR-05403903 Sao Paulo, SP - Brazil
[2] Adolfo Lutz Inst, BR-01246000 Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Immunotherapy; v. 10, n. 10, p. 871-885, AUG 2018.
Web of Science Citations: 2
Abstract

Aims: A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. Patients \& Methods: Monocytes obtained from 17 HIV-infected individuals were differentiated into MDDCs and, after loading with autologous HIV, the cells were characterized concerning surface molecule expression, migratory and phagocytosis capacity, cytokine production and the induction of an effective cell-mediated immune response. Results: The MDDCs were able to induce antigen-specific responses in autologous CD4+ and CD8+ T lymphocytes. Conclusions: Despite a large interindividual variability, the results suggested that MDDCs present the potential to promote immune responses in vaccinated patients. (AU)

FAPESP's process: 12/18879-6 - Characterization of dendritic cells used in an anti-HIV therapeutic vaccine clinical trial (Phase I/II)
Grantee:Telma Miyuki Oshiro Sumida
Support Opportunities: Regular Research Grants
FAPESP's process: 12/17822-0 - Characterization of dendritic cells used in a Phase I/II clinical trial of an anti-HIV therapeutic vaccine
Grantee:Laís Teodoro da Silva
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)